anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIMS: Arrhythmia-induced cardiomyopathy (AiCM) represents a subtype of acute heart failure (HF) in the context of sustained arrhythmia. Clear definitions and management recommendations for AiCM are lacking. The European Heart Rhythm Association Scientific Initiatives Committee (EHRA SIC) conducted a survey to explore the current definitions and management of patients with AiCM among European and non-European electrophysiologists.
METHODS AND RESULTS: A 25-item online questionnaire was developed and distributed among EP specialists on the EHRA SIC website and on social media between 4 September and 5 October 2023. Of the 206 respondents, 16% were female and 61% were between 30 and 49 years old. Most of the respondents were EP specialists (81%) working at university hospitals (47%). While most participants (67%) agreed that AiCM should be defined as a left ventricular ejection fraction (LVEF) impairment after new onset of an arrhythmia, only 35% identified a specific LVEF drop to diagnose AiCM with a wide range of values (5-20% LVEF drop). Most respondents considered all available therapies: catheter ablation (93%), electrical cardioversion (83%), antiarrhythmic drugs (76%), and adjuvant HF treatment (76%). A total of 83% of respondents indicated that adjuvant HF treatment should be started at first HF diagnosis prior to antiarrhythmic treatment, and 84% agreed it should be stopped within six months after LVEF normalization. Responses for the optimal time point for the first LVEF reassessment during follow-up varied markedly (1 day-6 months after antiarrhythmic treatment).
CONCLUSION: This EHRA Survey reveals varying practices regarding AiCM among physicians, highlighting a lack of consensus and heterogenous care of these patients.
Obesity has become a global health problem. In recent years, the influence of dietary microbes in the obese population has attracted the attention of scholars. Our study aimed to investigate the link between live microbe intake and obesity in adults. Participants (aged over 20 years) for this study were from the 1999-2018 National Health and Nutrition Examination Survey (NHANES). Participants were categorised into low, medium and high dietary live microbe intake groups. Linear regression was used to analyse the link between live microbe intake and body mass index (BMI) and waist circumference (WC). Logistic regression was used to analyse the link between live microbe intake and obesity and abdominal obesity prevalence. Restricted cubic spline curves (RCS) were used to check whether there was a non-linear relationship between live microbe intake and obesity. A total of 42,749 participants were included in this study and the number of obese reached 15,463. We found that live microbe intake was negatively linked to BMI and WC. In models adjusted for all confounders, the high live microbe intake group had lower obesity (OR = 0.812, 95%CI: 0.754-0.873) and abdominal obesity prevalence (OR = 0.851, 95%CI: 0.785-0.923) than the lowest intake group. Upon further quantification of live microbe intake, we found similar results. RCS analyses showed that live microbe intake was nonlinearly negatively correlated with BMI, WC, obesity, and abdominal obesity prevalence (P for non-linearity < 0.05). This study preliminarily reveals a negative link between live microbe intake and obesity in adults.
BACKGROUND: Patient heterogeneity poses significant challenges for managing individuals and designing clinical trials, especially in complex diseases. Existing classifications rely on outcome-predicting scores, potentially overlooking crucial elements contributing to heterogeneity without necessarily impacting prognosis.
METHODS: To address patient heterogeneity, we developed ClustALL, a computational pipeline that simultaneously faces diverse clinical data challenges like mixed types, missing values, and collinearity. ClustALL enables the unsupervised identification of patient stratifications while filtering for stratifications that are robust against minor variations in the population (population-based) and against limited adjustments in the algorithm's parameters (parameter-based).
RESULTS: Applied to a European cohort of patients with acutely decompensated cirrhosis (n = 766), ClustALL identified five robust stratifications, using only data at hospital admission. All stratifications included markers of impaired liver function and number of organ dysfunction or failure, and most included precipitating events. When focusing on one of these stratifications, patients were categorized into three clusters characterized by typical clinical features; notably, the 3-cluster stratification showed a prognostic value. Re-assessment of patient stratification during follow-up delineated patients' outcomes, with further improvement of the prognostic value of the stratification. We validated these findings in an independent prospective multicentre cohort of patients from Latin America (n = 580).
CONCLUSIONS: By applying ClustALL to patients with acutely decompensated cirrhosis, we identified three patient clusters. Following these clusters over time offers insights that could guide future clinical trial design. ClustALL is a novel and robust stratification method capable of addressing the multiple challenges of patient stratification in most complex diseases.
OBJECTIVES: I. Determine partial and complete response rates in patients with unresectable malignant mesothelioma treated with ecteinascidin 743. II. Determine the toxicity profile of this drug in these patients. III. Determine the pharmacokinetic/pharmacodynamic relationships of this drug in these patients. IV. Determine the duration of response, time to disease progression, 6-month progression-free survival, time to treatment failure, and overall survival of patients treated with this drug. V. Assess the quality of life of these patients treated with this drug.

OUTLINE: This is a multicenter study. Patients receive ecteinascidin 743 IV over 3 hours on day 1. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 2 additional courses after achieving CR. Quality of life is assessed at baseline and at the beginning of each course of therapy. Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 20-36 patients will be accrued for this study within 12-24 months.
The present disclosure relates to systems and methods of performing session trials. A computing system may select, for a session trial for subject, (i) a first image from a plurality of images of expressions associated with a subject, (ii) a second image associated with another subject, and (iii) a third image corresponding to one of a plurality of types for the condition. The computing system may provide, for presentation of the session trial to the subject, (i) the first image, (ii) the second image, and (iii) the third image, in accordance with a presentation parameter. The computing system may receive, from the subject, a response identifying an association of the third image with one of the first image or the second image. The computing system may determine a performance metric based on the association. The computing system may update, using the performance metric, the presentation parameter.
A system for providing to a patient a user experience for securely submitting a prescription to a pharmacy is provided. The system receives a notification of a prescription prescribed by a prescriber for the patient. The system displays to the patient information on drug options relating to the prescribed drug. The system then receives from the patient a selection of a drug option. The system displays to the patient pharmacy options relating to the selected drug option. Each pharmacy option identifies a pharmacy. The system receives from the patient a selection of a pharmacy option. The system then directs that an indication of the prescription be sent to the pharmacy identified by the selected pharmacy option so that that pharmacy can dispense the prescription.
FIELD: medicine, narcology. SUBSTANCE: method involves determination of blood plasma prolactin content during remission every month. Tactivin is prescribed if this index is increased by 30%, not less, as compared with normal value. Tactivin is administrated by subcutaneous route at the dose 1.0 every day for 5-7 days. EFFECT: prolonged remission period. 2 ex
In the last years magnetic resonance imaging (MRI) as well as positron emission tomography (PET) of the prostate have emerged as promising imaging tools. MRI provides mainly morphologic information and, to an increasing degree, functional information on the tumor microenvironment by using multiparametric approaches leading to an increase in diagnostic accuracy. Transition and periurethral zone cancers and the identification of patients' individual risk (e.g. for the development of a metastatic disease after primary treatment) is still a limitation of this method. PET, concerning radiolabelled choline, provides functional and predicting data on tumor metabolism and aggressiveness and has been found to be of complimentary value to morphologic imaging but still with the caveat of false positive and false negative findings. To overcome these limitations of morphological and functional imaging techniques, hybrid imaging systems have been developed and introduced into clinical routine. Additionally, the recently developed 68Ga-labeled Prostate Specific Membrane Antigen (PSMA) provides a highly specific information on a possible metastatic spread of prostate cancer. Thus the combined use of PET-MRI has wide spread applications in prostate cancer diagnosis, staging and treatment planning.

The potentials of this novel technique in general and its impact on assessing patients' individual risk to support a therapy or active surveillance decision in a future modified urological patient management were not yet explored in detail, but an initial prospective clinical trial in 38 patients with a sequential PET/MRI technique demonstrated the ability of a significant improvement of the individual methods. This registered prospective, randomized clinical trial is intended to proof, in a first step, the superiority of PET/MRI vs. the actual clinical standard procedures by applying a stable multiparametric metabolic hybrid imaging protocol. The aim of this study is to reduce the number of unnecessary invasive procedures to a minimum (image guided biopsy) and to enable superior image guided risk stratification.

In this prospective, randomized, multi-arm, multi-treatment clinical trial 220 subjects will be included at 1 site within 3 years. With a maximum follow-up for an early biochemical relapse of 2 years the planned duration should not exceed 5 years. The primary objective will be answered after 36 months.
OBJECTIVE: Kidney failure is highly prevalent in patients with non-ST-elevation myocardial infarction (NSTEMI). The aim of the study was to evaluate the prognostic significance of baseline renal function regarding in-hospital and 1-year mortality among patients with NSTEMI and treated with percutaneous coronary intervention (PCI).
METHODS: Data were obtained from the Polish Registry of Acute Coronary Syndromes (PL-ACS) and included 47,052 NSTEMI patients treated with PCI between 2017 and 2021. The cumulative incidence of all-cause mortality during the 1-year follow-up was presented using the Kaplan-Meier curves. The multivariable Cox regression model was created to adjust the relationship between eGFR (as a spline term) and all-cause mortality for potential confounders.
RESULTS: After considering the exclusion criteria, 20,834 cases were evaluated, with a median eGFR of 72.7 (IQR 56.6-87.5) mL/min/1.73 m2. The median age was 69 (62-76) years. The study comprised 4,505 patients with normal (90-120), 10,189 with mild (60-89), 5,539 with moderate (30-59), and 601 with severe eGFR impairment (15-29). Lower eGFR was associated with worse baseline clinical profile and longer in-hospital delay to coronary angiography. There was a stepwise increase in the crude all-cause death rates across the groups at 1 year. The Cox regression model with a spline term revealed that the relationship between eGFR and the risk of death at 1 year was non-linear (reverse J-shaped), and the risk was the lowest in patients with eGFR∼90 mL/min/1.73 m2.
CONCLUSIONS: There is a J-curve relationship between the eGFR value and 1-year all-cause mortality in patients with NSTEMI and treated with PCI.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to field of medicine and veterinary, namely to chemical-pharmaceutical industry, in particular to psychotropic medications. Invention represents pharmaceutical composition, which contains mixture of zolpidem and -cyclodextrin solutions in dimethyl sulfoxide with molar ratio of components from 1:1 to 10:1 with the following final concentration of components in composition based on 0.9% sodium chloride solution: zolpidem 1ù10-4 M, -cyclodextin - from 1ù10-5 to 1ù10-4 M, dimethyl sulfoxide - 10%. Invention can be used for optimisation of adaptive capacities in extreme situations; for treatment of insomnia; correction of anxiety disorders, neuroses, increased nervous excitability or depression; treatment of somatic diseases, accompanied by sleep disorders (syndrome of obstructive sleep apnea-hypopnea, cardio-vascular and nervous system diseases); optimisation of "sleep-wake" cycle in stress situations. ^ EFFECT: invention possesses sedative, nootropic and anxiolytic action, without causing side effects in form of myorelaxation and inhibition of actibating systems of brain stem, characteristic of sedative medications with anxiolytic activity. ^ 3 ex
No data are available in regard to human overdosage with or accidental oral ingestion of Timolol Maleate Ophthalmic Gel Forming Solution.

There have been reports of inadvertent overdosage with timolol maleate ophthalmic solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest (see also ADVERSE REACTIONS).

Overdosage has been reported with timolol maleate tablets. A 30-year-old female ingested 650 mg of timolol maleate tablets (maximum recommended oral daily dose is 60 mg) and experienced second and third degree heart block. She recovered without treatment but approximately two months later developed irregular heartbeat, hypertension, dizziness, tinnitus, faintness, increased pulse rate, and borderline first degree heart block.

An in vitro hemodialysis study, using 14C timolol added to human plasma or whole blood, showed that timolol was readily dialyzed from these fluids; however, a study of patients with renal failure showed that timolol did not dialyze readily.
Background : Upper GI endoscopy is often performed in patients with chronic liver disease to screen for esophageal and gastric varices. AIM: The purpose of this study is to compare propofol to midazolam for sedation in patients with chronic liver disease undergoing diagnostic upper GI endoscopy. Methods: 60 outpatients who has known chronic liver disease (Child-Pugh class A or B) (cirrhosis) and are undergoing variceal screening will be randomized to receive propofol or midazolam for sedation. Administration of sedation was performed by a anesthesist. Outcome measures studied are induction and recovery times, efficacy and safety of sedation, patient satisfaction, and return to baseline function and subclinical hepatic encephalopathy (number connection test), and saturation of oxygen. expected results: The mean time to achieve adequate sedation will be shorter for for the propofol group in comparison to midazolam group. The level of sedation achieved by the propofol group will be greater. Time to full recovery will be faster in the propofol group. Propofol do not exacerbate subclinical hepatic encephalopathy as compared to midazolam. patients receiving propofol will express greater overall mean satisfaction with the quality of their sedation at the time of discharge. Conclusions: Propofol sedation is expected not to exacerbate subclinical hepatic encephalopathy in cirrhotics.
The invention discloses Docynia delavayi(Franch.)Schneid. plant extract as well as a combined application of Docynia delavayi(Franch.)Schneid. serving as a cosmetic additive with functions of skin whitening and moistening and with antioxidant activity in preparation of cosmetics. Docynia delavayi(Franch.)Schneid. extract is water extract or ethanol extract of Docynia delavayi(Franch.)Schneid., has good DPPH (2,2-diphenyl-1-picrylhydrazyl) free radical scavenging capacity and is a good natural antioxidant. In terms of human skin care, the Docynia delavayi(Franch.)Schneid. extract has excellent potential in application of skin cosmetics with anti-wrinkling, whitening and sun protection functions and the like. The medicinal plant from a Chinese traditional minority, Docynia delavayi(Franch.)Schneid. is effectively used for preparation of the Docynia delavayi(Franch.)Schneid. extract with very high activity for skin cosmetics, the extract can be used for preparation of cosmetics, is a good antioxidant, has excellent anti-wrinkling, whitening, sun protection functions and the like and is a good natural plant cosmetic raw material.
Overdoses of topiramate have been reported. Signs and symptoms included convulsions, drowsiness, speech disturbance, blurred vision, diplopia, impaired mentation, lethargy, abnormal coordination, stupor, hypotension, abdominal pain, agitation, dizziness and depression. The clinical consequences were not severe in most cases, but deaths have been reported after overdoses involving topiramate.

Topiramate overdose has resulted in severe metabolic acidosis [see Warnings and Precautions (5.4)] . 

A patient who ingested a dose of immediate-release topiramate between 96 g and 110 g was admitted to a hospital with a coma lasting 20 to 24 hours followed by full recovery after 3 to 4 days.

Similar signs, symptoms, and clinical consequences are expected to occur with overdosage of QUDEXY XR. Therefore, in the event of QUDEXY XR overdose, QUDEXY XR should be discontinued and general supportive treatment given until clinical toxicity has been diminished or resolved.

Hemodialysis is an effective means of removing topiramate from the body.
COPD EXACERBATIONS. COPD exacerbations, characterized by an acute worsening of dyspnea and/or cough and sputum volume beyond daily variations, are a public health issue because of their frequency, the number of hospitalizations and the high rate of recurrence. Because of non-specific symptoms, differential diagnoses must be ruled out. Additional tests are rarely necessary, and treatment is outpatient, except in severe cases (respiratory distress, severity of COPD, socio-economic conditions). Increased bronchodilator treatment, and sometimes antibiotic and/or systemic corticosteroid therapy, are the main measures to be introduced and should be systematically reassessed. After an exacerbation, the aim is to optimize follow-up and treatment, to prevent recurrences.
The development of a potentially life-threatening serotonin syndrome has been reported with Cyclobenzaprine Hydrochloride when used in combination with other drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. The concomitant use of Fexmid with MAO inhibitors is contraindicated (see CONTRAINDICATIONS). Serotonin syndrome symptoms may include mental status changes (e.g., confusion, agitation, hallucinations), autonomic instability (e.g., diaphoresis, tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (e.g., tremor, ataxia, hyperreflexia, clonus, muscle rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Treatment with Fexmid and any concomitant serotonergic agents should be discontinued immediately if the above reactions occur and supportive symptomatic treatment should be initiated. If concomitant treatment with Fexmid and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dose increases (see PRECAUTIONS,Drug Interactions).

Fexmid is closely related to the tricyclic antidepressants, e.g., amitriptyline and imipramine. In short term studies for indications other than muscle spasm associated with acute musculoskeletal conditions, and usually at doses somewhat greater than those recommended for skeletal muscle spasm, some of the more serious central nervous system reactions noted with the tricyclic antidepressants have occurred (see WARNINGS, below, and ADVERSE REACTIONS).

Tricyclic antidepressants have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke.

Fexmid may enhance the effects of alcohol, barbiturates, and other CNS depressants.
PURPOSE:To obtain Epidermal Growth Factor by a simple operation, efficiently, by subjecting a solution containing Epidermal Growth Factor to ultrafiltration with an ultrafilter having specific fractional molecular weight. CONSTITUTION:A solution containing Epidermal Growth Factor (EGF for short) is subjected to ultrafiltration with an ultrafilter having <=10,000, preferably 500-5,000 fractional molecular weight, to remove high polymer impurities. In the ultrafiltration, filtration rate and purification degree are raised. EGF is not passed through the ultrafilter, separated from the filtrate and concentrated. Heating during operation is not required and EGF is not deactivated. The filtration system can be repeatedly used and the treatment rate is extremely high.
The present invention relates to a composition which is obtained by the extraction and the separation of ixeris sonchifolia hance and contains active compounds of the glucoside of ixeris sonchifolia hance inner ester A-1 (I) and the glucoside of ixeris sonchifolia hance inner ester B-1 (II), a relevant derivate thereof and a preparation method thereof. The content of the I and II in the composition of the ixeris sonchifolia hance inner ester is greater than 10%, and is less than 98%, wherein the proportion of I to II is 10 to 1: 1 to 10. The aglycone composition of the ixeris sonchifolia hance inner ester can be obtained from compounds I and II through the hydrolysis of glucosyl on R1. The whole herb of ixeris sonchifolia hance is cut up, the whole herb is boiled with water, concentrated, recovered and filtered, and finally, the composition is obtained by alumina gel column chromatography after alumina column chromatography. The composition and the relevant derivate thereof are suitable for being prepared into various single medicament preparations, and can be prepared into slow release or release control medicament preparations. The various single medicament preparations and the slow release or release control medicament preparations can be used for treating various kinds of tumours and cancer.
FIELD: medicine, pharmaceutical technology. SUBSTANCE: method involves multistep fermentation of fresh medicinal plants and bioactive substances are isolated using food solvent followed by filtration and pouring. The first stage of fermentation is carried out separately for each plant species under intensive ultraviolet irradiation and at natural temperature modulations during 24 h. The second stage of fermentation is carried out at temperature below 15 C under control of its termination by precipitate formed. After the first stage of fermentation solid fraction is separated from liquid one followed by filtration. After the second stage of fermentation liquid fraction is separated by decanting from precipitate followed by its filtration. Then all components of obtained oils are combined and settled for natural maturation for 3-4 months. Fermented curative-prophylactic agent can be used as biologically active addition to food, gel-base preparations, suppository, colloidal films. EFFECT: increased yield of active matters to end product. 1 ex